Literature DB >> 23878043

Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age.

Caroline Breese Hall1, Geoffrey A Weinberg, Aaron K Blumkin, Kathryn M Edwards, Mary A Staat, Andrew F Schultz, Katherine A Poehling, Peter G Szilagyi, Marie R Griffin, John V Williams, Yuwei Zhu, Carlos G Grijalva, Mila M Prill, Marika K Iwane.   

Abstract

BACKGROUND: Respiratory syncytial virus (RSV) infection is a leading cause of hospitalization among infants. However, estimates of the RSV hospitalization burden have varied, and precision has been limited by the use of age strata grouped in blocks of 6 to ≥ 12 months.
METHODS: We analyzed data from a 5-year, prospective, population-based surveillance for young children who were hospitalized with laboratory-confirmed (reverse-transcriptase polymerase chain reaction) RSV acute respiratory illness (ARI) during October through March 2000-2005. The total population at risk was stratified by month of age by birth certificate information to yield hospitalization rates.
RESULTS: There were 559 (26%) RSV-infected children among the 2149 enrolled children hospitalized with ARI (85% of all eligible children with ARI). The average RSV hospitalization rate was 5.2 per 1000 children <24 months old. The highest age-specific rate was in infants 1 month old (25.9 per 1000 children). Infants ≤ 2 months of age, who comprised 44% of RSV-hospitalized children, had a hospitalization rate of 17.9 per 1000 children. Most children (79%) were previously healthy. Very preterm infants (<30 weeks' gestation) accounted for only 3% of RSV cases but had RSV hospitalization rates 3 times that of term infants.
CONCLUSIONS: Young infants, especially those who were 1 month old, were at greatest risk of RSV hospitalization. Four-fifths of RSV-hospitalized infants were previously healthy. To substantially reduce the burden of RSV hospitalizations, effective general preventive strategies will be required for all young infants, not just those with risk factors.

Entities:  

Keywords:  acute respiratory illness; respiratory syncytial virus

Mesh:

Year:  2013        PMID: 23878043     DOI: 10.1542/peds.2013-0303

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  181 in total

1.  Hepatitis B Virus Core Particles Containing a Conserved Region of the G Protein Combined with Interleukin-35 Protected Mice against Respiratory Syncytial Virus Infection without Vaccine-Enhanced Immunopathology.

Authors:  Jie Yang; Chen Ma; Yu Zhao; Anjing Fan; Xiufen Zou; Zishu Pan
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

2.  Reduced-Dose Schedule of Prophylaxis Based on Local Data Provides Near-Optimal Protection Against Respiratory Syncytial Virus.

Authors:  Daniel M Weinberger; Joshua L Warren; Claudia A Steiner; Vivek Charu; Cécile Viboud; Virginia E Pitzer
Journal:  Clin Infect Dis       Date:  2015-04-22       Impact factor: 9.079

Review 3.  Respiratory Syncytial Virus Infection: An Illness for All Ages.

Authors:  Edward E Walsh
Journal:  Clin Chest Med       Date:  2016-12-27       Impact factor: 2.878

4.  Environmental Cadmium Enhances Lung Injury by Respiratory Syncytial Virus Infection.

Authors:  Xin Hu; Ki-Hye Kim; Youri Lee; Jolyn Fernandes; M Ryan Smith; Yu-Jin Jung; Michael Orr; Sang-Moo Kang; Dean P Jones; Young-Mi Go
Journal:  Am J Pathol       Date:  2019-05-18       Impact factor: 4.307

5.  Novel diversity-oriented synthesis-derived respiratory syncytial virus inhibitors identified via a high throughput replicon-based screen.

Authors:  Jeremy R Duvall; Lynn VerPlank; Barbara Ludeke; Sarah M McLeod; Maurice D Lee; Karthick Vishwanathan; Carol A Mulrooney; Sebastian Le Quement; Qin Yu; Michelle A Palmer; Paul Fleming; Rachel Fearns; Michael A Foley; Christina A Scherer
Journal:  Antiviral Res       Date:  2016-04-06       Impact factor: 5.970

Review 6.  Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein.

Authors:  Jason S McLellan
Journal:  Curr Opin Virol       Date:  2015-03-26       Impact factor: 7.090

7.  Virus-Specific Antibody, Viral Load, and Disease Severity in Respiratory Syncytial Virus Infection.

Authors:  Edward E Walsh; Lu Wang; Ann R Falsey; Xing Qiu; Anthony Corbett; Jeanne Holden-Wiltse; Thomas J Mariani; David J Topham; Mary T Caserta
Journal:  J Infect Dis       Date:  2018-06-20       Impact factor: 5.226

Review 8.  Bronchodilators for bronchiolitis.

Authors:  Anne M Gadomski; Melissa B Scribani
Journal:  Cochrane Database Syst Rev       Date:  2014-06-17

Review 9.  Lamb model of respiratory syncytial virus-associated lung disease: insights to pathogenesis and novel treatments.

Authors:  Mark R Ackermann
Journal:  ILAR J       Date:  2014

10.  Identifying Gaps in Respiratory Syncytial Virus Disease Epidemiology in the United States Prior to the Introduction of Vaccines.

Authors:  Lindsay Kim; Brian Rha; Jon S Abramson; Larry J Anderson; Carrie L Byington; Grace L Chen; John DeVincenzo; Kathryn M Edwards; Janet A Englund; Ann R Falsey; Marie R Griffin; Ruth A Karron; Karen G Martin; H Cody Meissner; Flor M Munoz; Andrew T Pavia; Pedro A Piedra; William Schaffner; Eric A F Simões; Rosalyn Singleton; H Keipp Talbot; Edward E Walsh; Jane R Zucker; Susan I Gerber
Journal:  Clin Infect Dis       Date:  2017-09-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.